Brought to you by 
Turnstone Biologics closes $11.3mm Series A
29 Oct 2015
Executive Summary
Turnstone Biologics Inc. (developing oncolytic virus-based therapies for cancer) raised $11.3mm through its Series A round led by Versant Ventures. Founding investor FACIT (Fight Against Cancer Innovation Trust; established by the Ontario Institute for Cancer Research) also participated. Versant takes two board seats.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Vaccines
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Turnstone Biologics closes $11.3mm Series A
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice